Literature DB >> 22477299

Dose-dependency in pleiotropic effects of atorvastatin.

Masatoshi Fujita1, Tatsuya Morimoto, Masaki Ikemoto, Mayu Takeda, Akiko Ikai, Kunihisa Miwa.   

Abstract

Statins are recognized as the principal and most effective class of drugs for reducing serum cholesterol levels and, therefore, significantly reducing cardiovascular events and mortality. Statins may have a wide range of beneficial biological effects in addition to lipid lowering, a phenomenon commonly termed a 'pleiotropic effect'. However, the dose-dependency of these effects remains unclear. The present study evaluated whether atorvastatin, a potent statin, ameliorates the serum markers of pleiotropic effects, with a focus on dose-dependency. The pleiotropic effects of treatment with atorvastatin 5 mg/day and 10 mg/day for six months each in 15 patients with primary hypercholesterolemia were assessed in a prospective, randomized, open-label, crossover, single-centre study. Atorvastatin treatment dose-dependently decreased a serum marker of oxidative stress as well as the serum low-density lipoprotein cholesterol level. However, serum markers of inflammation and fibrinolysis decreased independently of dose. In conclusion, the dose-dependency of atorvastatin's pleiotropic effects differs among individual biological effects.

Entities:  

Year:  2007        PMID: 22477299      PMCID: PMC2733023          DOI: 10.1055/s-0031-1278256

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  15 in total

1.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.

Authors:  M A Albert; E Danielson; N Rifai; P M Ridker
Journal:  JAMA       Date:  2001-07-04       Impact factor: 56.272

2.  Intensive statin therapy--a sea change in cardiovascular prevention.

Authors:  Eric J Topol
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245

3.  HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.

Authors:  S Wassmann; U Laufs; A T Bäumer; K Müller; K Ahlbory; W Linz; G Itter; R Rösen; M Böhm; G Nickenig
Journal:  Hypertension       Date:  2001-06       Impact factor: 10.190

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

5.  Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.

Authors:  Y Rikitake; S Kawashima; S Takeshita; T Yamashita; H Azumi; M Yasuhara; H Nishi; N Inoue; M Yokoyama
Journal:  Atherosclerosis       Date:  2001-01       Impact factor: 5.162

6.  Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically proven coronary artery disease.

Authors:  Abdullah Tekin; Göknur Tekin; Deniz Güzelsoy; Ayşem Kaya; Ciğdem Vural Gürel; Zerrin Yiğit; Turgut Ulutin
Journal:  Am J Cardiol       Date:  2004-07-15       Impact factor: 2.778

7.  Analytical performance of the Synchron LX20 Pro, BN trade mark II and IMMAGE high sensitivity C-reactive protein assays and concordance in cardiovascular risk stratification.

Authors:  Valerie C McWhorter; Lynne C Ford; Anthony W Butch
Journal:  Clin Chim Acta       Date:  2004-09       Impact factor: 3.786

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.

Authors:  Rory Collins; Jane Armitage; Sarah Parish; Peter Sleight; Richard Peto
Journal:  Lancet       Date:  2004-03-06       Impact factor: 79.321

Review 10.  Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease.

Authors:  B G Brown; X Q Zhao; D E Sacco; J J Albers
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

View more
  4 in total

1.  Effect of Atorvastatin on Serum Para-Oxonase-1 and C-Reactive Protein in Wistar Rats.

Authors:  Aradhana Marathe; B Ganaraja; K Ashwin Shenoy; K Ashok Prabhu; M Nandini
Journal:  Indian J Clin Biochem       Date:  2018-03-17

2.  A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts.

Authors:  Mojca Lunder; Miodrag Janić; Lovro Žiberna; Gorazd Drevenšek; Mišo Šabovič
Journal:  Med Sci Monit       Date:  2012-09

3.  A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.

Authors:  Sarai Rodríguez; Imma Raurell; Manuel Torres-Arauz; Teresa García-Lezana; Joan Genescà; María Martell
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

Review 4.  Statin Therapy in Post-Operative Atrial Fibrillation: Focus on the Anti-Inflammatory Effects.

Authors:  Homa Nomani; Amir Hooshang Mohammadpour; Željko Reiner; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  J Cardiovasc Dev Dis       Date:  2021-02-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.